Tarsheen K. Sethi, MBBS, MD

Tarsheen K. Sethi, MBBS, MD

Clinical Fellow, Hematology/Oncology

Combination of Rituximab, Lenalidomide and Nivolumab for relapsed/ refractory activated B cell (ABC) type diffuse large B cell lymphoma (DLBCL) including Primary Central Nervous System Lymphoma (PCNSL): A Phase 1/2 Trial

Mentor: Nishitha Reddy, MD, MSCI

Research Description

PET- adapted sequential salvage therapy with Nivolumab followed by Ifosfamide, Carboplatin, and Etoposide for patients with relapsed or refractory Hodgkin’s Lymphoma